Tumor Agnostic Role of TMB Biomarker Faces Challenges
August 18th 2022Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.
Tumor Agnostic Approval Targets BRAF V600E–Mutant Disease
August 15th 2022Vivek Subbiah, MD, discusses the significance of the approval of dabrafenib plus trametinib for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors and highlights future directions for tumor agnostic drug development.